Anika Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
11/03/2024 20:04
* Anika Therapeutics Inc ANIK.OQ ANIK.O is expected
to show a
rise in quarterly revenue when it reports results on March 13
for the period ending December 31 2023
* The Bedford Massachusetts-based company is expected to
report a
4.5% increase in revenue to $41.405 million from $39.62 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Anika Therapeutics Inc
is for
a loss of 26 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Anika
Therapeutics Inc is $29.00, above its last closing price
of $25.42.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.38 -0.37 -0.45 Missed -20.5
Jun. 30 2023 -0.27 -0.27 -0.19 Beat 29.6
Mar. 31 2023 -0.33 -0.30 -0.47 Missed -56.7
Dec. 31 2022 -0.25 -0.24 -0.34 Missed -41.7
Sep. -0.25 -0.25 -0.15 Beat 40
30 2022
Jun. 30 2022 -0.21 -0.23 -0.20 Beat 11.8
Mar. 31 2022 -0.37 -0.36 -0.20 Beat 45.2
Dec. 31 2021 -0.29 -0.25 -0.40 Missed -58.4
This summary was machine generated March 11 at 20:04 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)